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Objectives: Posthoc analysis of treatment satisfaction in patients switching to subcutaneous 
(SC) peginterferon beta-1a in the ALLOW study.
Patients and methods: Patients with relapsing multiple sclerosis treated with intramuscular 
interferon (IFN) beta-1a or SC IFN beta-1a or beta-1b remained on their current therapy for 
a 4-week run-in period, followed by a switch to SC peginterferon beta-1a 125 mcg every 2 
weeks for 48 weeks. Treatment satisfaction was measured using the Treatment Satisfaction 
Questionnaire for Medication (TSQM), which covers effectiveness, side effects, convenience, 
and global satisfaction. Patients completed the TSQM at baseline (prior to starting the 4-week 
run-in period) and 4, 12, 24, 36, and 48 weeks after switching, and scores were analyzed for the 
overall population and compared to baseline. Patients reported the severity of flu-like symptoms 
(FLS) at baseline and with each peginterferon beta-1a injection; clinicians evaluated the occur-
rence of injection-site reactions (ISRs) after the first dose of peginterferon beta-1a and every 
12 weeks thereafter. TSQM scores were stratified by the presence of FLS or ISRs during the 
study period and by prior IFN therapy use.
Results: For the overall population (n=194), convenience and global satisfaction scores signifi-
cantly improved from baseline at all time points, and side effect satisfaction scores significantly 
improved up to week 36. Convenience scores significantly improved regardless of FLS, ISRs, 
or prior IFN therapy. Patients without FLS during the study period showed significant improve-
ments in global satisfaction, but not side effect satisfaction, versus those with FLS. Patients 
switching from SC IFN therapies achieved greater improvements in treatment satisfaction than 
patients who switched from intramuscular IFN beta-1a.
Conclusions: Switching relapsing multiple sclerosis patients to SC peginterferon beta-1a from 
other IFN therapies significantly improved treatment satisfaction and convenience.
Keywords: interferon beta-1a, interferon beta-1b, peginterferon beta-1a, relapsing multiple 
sclerosis, treatment satisfaction, Treatment Satisfaction Questionnaire for Medication, TSQM, 
quality of life, patient-reported outcomes
Introduction
Interferon (IFN) beta-based disease-modifying therapies (DMTs) are well-established 
treatments approved for relapsing forms of multiple sclerosis (RMS). Intramuscular 
(IM) IFN beta-1a, subcutaneous (SC) IFN beta-1a, and SC IFN beta-1b have well-
characterized efficacy and safety profiles.1,2 SC peginterferon beta-1a is the most recently 
approved IFN for the treatment of RMS, is administered every 2 weeks, and has a safety 
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and tolerability profile consistent with the IFN class, with the 
most common adverse events (AEs) including flu-like symp-
toms (FLS) and injection-site reactions (ISRs).3–5 However, in 
a Phase I crossover study in healthy volunteers, AEs occurred 
less frequently with SC peginterferon beta-1a than with SC 
IFN beta-1a three times a week over 2 weeks despite 60% 
higher levels of drug exposure.3 In addition, the ALLOW 
study, a Phase IIIb, open-label, randomized study in patients 
with RMS who switched from a nonpegylated IFN to peginter-
feron beta-1a, found the vast majority of patients (89.6%) did 
not show new or worsening FLS after the switch.6,7
While the primary objective of ALLOW was to assess 
FLS in patients switching to peginterferon beta-1a,6,7 par-
ticipating patients also reported their satisfaction with the 
therapy. Patient-reported treatment satisfaction is based on 
factors such as convenience (eg, route of administration and 
dosing frequency), effectiveness, and side effects.8,9 Treat-
ment satisfaction has also been shown to affect treatment 
adherence and persistence; nonadherence to DMTs has 
been associated with reduced treatment effectiveness (eg, 
increased relapse/progression) and may lead to increased 
hospitalization rates and MS-related costs.10,11 These findings 
highlight the ongoing need to evaluate and improve patients’ 
treatment satisfaction.12 Monitoring treatment satisfaction 
may also help to identify patients who may be at risk of 
poor medication adherence,13 highlighting an opportunity to 
change medication or implement patient education.
Patient-reported treatment satisfaction has been measured 
using a variety of instruments, including the Treatment 
Satisfaction Questionnaire for Medication (TSQM), a vali-
dated, psychometrically sound measure for the assessment 
of patients’ satisfaction with medication.13 The TSQM has 
been validated in patients with RMS and has been used to 
measure satisfaction with DMTs.12,14
This posthoc analysis was conducted to assess patient-
reported treatment satisfaction in patients with RMS who 
switched from a nonpegylated IFN beta therapy to SC 
peginterferon beta-1a as a part of the ALLOW study.
Patients and methods
The ALLOW study design has been described previously.6,7 
The study enrolled patients aged 18–65 years with RMS 
treated with a stable dose of nonpegylated IFN for $4 months 
immediately prior to screening. Patients remained on their 
current therapy for a 4-week run-in period followed by a 
switch to SC peginterferon beta-1a (125 mcg every 2 weeks) 
and were followed for a total of 48 weeks.
The primary end point of the ALLOW study was the propor-
tion of patients experiencing new or worsening FLS during the 
first 8 weeks of SC peginterferon beta-1a therapy.6,7 Secondary 
end points included patient-reported treatment satisfaction.
Patients completed the TSQM at baseline (prior to the 
run-in period when patients were receiving nonpegylated 
IFN) and 4, 12, 24, 36, and 48 weeks after switching to 
peginterferon beta-1a. The TSQM comprises 14 items cover-
ing four domains: effectiveness, side effects, convenience, 
and global satisfaction.13,14 The TSQM items utilize a 5- or 
7-point Likert-type scale. A score for each domain is calcu-
lated by summing the corresponding items transformed on a 
0–100 scale; higher values indicate higher satisfaction.15
TSQM scores at baseline were compared to TSQM scores 
at each postswitching visit for the overall efficacy popula-
tion, defined as patients who received at least one dose of SC 
peginterferon beta-1a and had TSQM data during the 4-week 
run-in period and during the postswitching treatment period. 
All data were analyzed using observed data; no imputation 
was performed for missing data. TSQM scores were analyzed 
for the impact of ISRs or FLS occurrence at any point during 
the study, as well as by prior IFN therapy. FLS were assessed 
using the total FLS score (FLS-S). Patients were assigned a 
score from 0 to 3 to their muscle aches, chills, and fatigue as 
follows: “0” for absent; “1” for mild, did not interfere with 
daily activities; “2” for moderate, sufficient to interfere with 
daily activities; and “3” for severe, bedrest required. Patients’ 
body temperatures were also assigned a score from 0 to 3: “0” 
if ,99.1°F, “1” if $99.1°F but ,100.1°F, “2” if $100.1°F 
but ,101.1°F, and “3” if $101.1°F, allowing a total FLS-S 
ranging from 0 to 12. As defined in the protocol for the pri-
mary end point for the study, a patient with an FLS-S increase 
of $2 from the 4-week run-in period was regarded as having 
FLS. The effect of prior IFN therapy on changes in baseline 
TSQM scores was compared in patients previously treated 
with IM IFN beta-1a or SC IFN beta-1a or beta-1b.
Changes from baseline were recorded using transformed 
scores between 0 and 100 and analyzed using a paired t-test 
and a significance level of 0.05. Linear regression analysis 
was used over all visits. Comparisons between prior IFN 
therapies, FLS status, and ISR status were analyzed using 
a two-sample t-test and a significance level of 0.05. To jus-
tify the use of t-tests, data were also analyzed by Wilcoxon 
signed-rank test or Wilcoxon rank-sum tests; P-values from 
the two types of tests were similar.
The study was performed in accordance with the Decla-
ration of Helsinki and in compliance with the International 
Council for Harmonisation and Good Clinical Practice. The 
study protocol and amendments were approved by each study 
site’s local ethics committee (Table S1), and all patients 
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Improved satisfaction among MS patients on peginterferon beta-1a therapy
Results
Patients
Of the 201 patients randomized into ALLOW, 164 (81.6%) 
completed the study. Reasons for not completing the study 
were withdrawal due to AEs (13.4%), consent withdrawn 
(3.5%), and others (1.5%). The intent-to-treat (ITT) popula-
tion (the cohort for ALLOW study analysis) comprised 201 
randomized patients who received at least one dose of SC 
peginterferon beta-1a. Baseline characteristics of the ITT 
population are shown in Table S2. The efficacy population 
consisted of 194 randomized patients who received at least 
one dose of SC peginterferon beta-1a and had efficacy data 
at baseline and postswitching, the cohort for the current 
analysis. No differences were seen in baseline characteristics 
between the ITT and efficacy populations.
Nonpegylated IFN therapies taken prior to switching 
across the ITT population (n=201) were IM IFN beta-1a 
(50.8%), SC IFN beta-1a (25.4%), SC IFN beta-1b (19.4%), 
and unknown (4.5%).
TSQM scores: overall efficacy population
Changes from baseline to each postswitching visit using 
transformed scores between 0 and 100 are presented for 
the overall efficacy population in Figure 1. The changes 
from baseline in convenience and global satisfaction scores 
were statistically significant at all postswitching time points 
through week 48 (all P,0.0001; Figure 1). Side effect scores 
were also significantly improved compared with baseline 
for all visits (P,0.05) except week 48. Trends toward 
small improvements in effectiveness scores were seen at 
later time points, although the changes were not statistically 
significant.
TSQM scores: by FLS status
A quarter (49/194) of patients experienced FLS at any point 
in the study. We analyzed TSQM scores in patients who 
did versus those who did not experience FLS to determine 
whether FLS had any impact on treatment satisfaction.
Regardless of whether patients experienced FLS, signifi-
cant improvements in mean TSQM side effect scores were 
observed from baseline to week 4, returning to near-baseline 
levels by week 48 (Figure 2). Significant improvements 
in mean TSQM convenience scores from baseline to each 
subsequent study visit were seen regardless of FLS (all 
P,0.0001).
Patients who did not experience FLS reported significant 
improvements from baseline in mean TSQM global satis-
faction at all subsequent visits (all P,0.0001). In contrast, 
patients who experienced FLS saw an improvement in 
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Figure 1 improvement in overall TsQM scores from baseline.
Notes: *P,0.05, ***P,0.001, and ****P,0.0001 compared with baseline. Data are mean values ±95% ci.
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week 4 (P,0.05). At all other time points, mean global sat-
isfaction scores were numerically higher than baseline but 
the difference was not statistically significant. Differences 
in TSQM global satisfaction between the two cohorts, with 
and without FLS, were statistically significant at weeks 12, 
24, and 36 (P,0.05; Figure 2).
Changes in effectiveness score (not shown) indicated 
a general improvement for patients both with and without 
FLS, but none of the changes were significantly different 
from baseline at any time point.
TSQM scores: by ISR status
ISRs were experienced by 64.4% (125/194) of patients at any 
point in the study. TSQM scores were analyzed in patients 
who did versus those who did not experience ISRs to deter-
mine the impact of ISRs on treatment satisfaction.
Statistically significant improvements in mean TSQM side 
effect scores were observed from baseline to all visits except 
week 24 for patients who experienced ISRs at any time point in 
the study (Figure 3). For patients who did not experience ISRs 
(69/194), numerical improvements in TSQM side effect scores 
were observed at weeks 4, 12, 24, and 36, and a numerical 
reduction was observed at week 48, but no significant changes 
from baseline values were observed at any time point.
Regardless of whether patients experienced ISRs, mean 
TSQM convenience scores were significantly improved from 
baseline to all subsequent visits (all P,0.0001). Similarly, 
whether or not patients experienced ISRs, mean TSQM 
global satisfaction scores were improved from baseline for 
all time points except at week 48.
No significant changes in mean TSQM effectiveness 
scores from baseline to any subsequent visit for patients 
with or without ISRs were seen at any point in the study 
(data not shown).
TSQM scores: by prior IFN
At screening, 97 patients were receiving IM IFN beta-1a 
and 89 were receiving SC IFN beta-1a or beta-1b. TSQM 
scores were analyzed by these two prior IFN therapy groups 
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Figure 2 improvement in TsQM scores (with or without Fls).
Notes: *P,0.05, **P,0.01, ***P,0.001, ****P,0.0001 compared with baseline. Data are mean values ±95% CI. A patient was considered to have FLS if FLS-S total score 
was .0 at any point in the study.
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Improved satisfaction among MS patients on peginterferon beta-1a therapy
changes in treatment satisfaction associated with the switch 
to peginterferon beta-1a.
After switching to peginterferon beta-1a, patients reported 
stable or improved mean TSQM side effect scores from base-
line to each visit (Figure 4). Mean TSQM side effect scores 
improved significantly more for patients transitioning from 
SC IFN beta-1a or beta-1b than for those transitioning from 
IM IFN beta-1a at weeks 24 and 36 (P,0.01). In general, for 
nonpegylated IFN therapies, the largest differences from base-
line were seen at the earlier time points, and values returned 
to baseline or near-baseline by the end of the study.
Mean TSQM convenience scores also significantly 
improved from baseline to each visit for both nonpegy-
lated IFN groups (all P,0.0001). The improvement was 
significantly larger at every visit for the SC IFN beta-1a or 
beta-1b treatment group compared with the IM IFN beta-1a 
treatment group.
Significant improvements in mean TSQM global satisfac-
tion scores from baseline were recorded in patients switching 
from SC IFN beta-1a or beta-1b to peginterferon beta-1a at all 
time points, while those previously on IM IFN beta-1a only 
showed significantly improved global satisfaction at weeks 
12, 36, and 48 (Figure 4). Improvements in global satisfac-
tion were significantly greater for the prior SC IFN beta-1a 
or beta-1b group compared with the IM IFN beta-1a group 
at weeks 4 and 24, with a trend toward greater improvement 
at other time points.
Irrespective of prior IFN treatment, TSQM effective-
ness scores were generally stable from baseline to each visit 
after the switch to peginterferon beta-1a (data not shown). 
Mean values showed a trend in improvement from baseline 
for patients in the SC IFN beta-1a or beta-1b group, but no 
changes were significantly different from baseline.
Discussion
The switch from nonpegylated IFNs to SC peginterferon 
beta-1a every 2 weeks led to significant improvements 
in patient satisfaction with side effects, convenience, and 
global satisfaction scores on the TSQM as early as 4 weeks 
after switching (the earliest time point assessed). Although 
effectiveness scores were numerically higher (better), no 
significant changes from baseline were seen, which was 
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Figure 3 improvement in TsQM scores (with or without isrs).
Notes: *P,0.05, **P,0.01, ***P,0.001, ****P,0.0001 compared with baseline. Data are mean values ±95% ci.
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expected given that the study did not select for patients who 
were switching due to lack of efficacy.
As FLS are one of the most common AEs associated with 
IFN therapies, we wanted to determine whether FLS influ-
ence treatment satisfaction after a switch to peginterferon 
beta-1a. Therefore, the data were analyzed by stratifying 
patients into those with or without FLS during the study. 
Patients reported improvements from baseline in side effects, 
convenience, and global satisfaction scores regardless of 
experiencing FLS. Interestingly, although patients without 
FLS showed significantly greater improvements in global 
satisfaction than those with FLS, no significant differences 
in side effect TSQM scores between the with-FLS and 
without-FLS treatment groups were seen, suggesting that 
the improvement in global satisfaction was most likely due 
to the improvement in convenience scores.
Notably, patients who experienced ISRs showed increased 
side effect satisfaction scores early after switching to peginter-
feron beta-1a. One explanation for this seemingly counter-
intuitive finding may be that these patients may have been 
experiencing ISRs more frequently with their previous more 
frequently dosed IFN therapy when compared with every- 
2-weeks dose administration with peginterferon beta-1a. This 
observation is consistent with the overall ALLOW study, 
in which the majority of FLS and ISR events were mild to 
moderate, with only 2.5% and 6% of patients, respectively, 
discontinuing due to these AEs.6
The switch from SC IFN beta-1a or beta-1b to SC 
peginterferon beta-1a was associated with significantly greater 
improvements in convenience and global satisfaction than the 
switch from IM IFN beta-1a. Furthermore, satisfaction with 
side effects was significantly improved following the treat-
ment switch for patients on prior SC IFN beta-1a or beta-1b, 
but only significant at one time point for patients on prior IM 
IFN beta-1a (week 4). This finding may relate back to the 
baseline incidence of ISRs, which tend to be more common 
with SC IFN beta-1a or beta-1b than with IM IFN beta-1a;16 
patients on prior SC IFN beta therapies are therefore likely to 
show greater improvement in satisfaction with side effects. 
Taken together, these results suggest that SC IFN beta-1a or 
beta-1b patients are likely to gain the greatest benefit in treat-
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Figure 4 improvement in TsQM scores (prior iFn treatment).
Notes: *P,0.05, **P,0.01, ***P,0.001, ****P,0.0001 compared with baseline. Data are mean values ±95% ci.
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Improved satisfaction among MS patients on peginterferon beta-1a therapy
This greater treatment satisfaction with peginterferon 
beta-1a is likely driven largely by differences in dosing 
schedule between the IFN therapies. In a 2-week period, 
patients on SC IFN beta-1a or beta-1b inject six or seven 
times, respectively; those on IM IFN beta-1a inject twice; and 
those on SC peginterferon beta-1a inject once. It is perhaps 
not surprising that patients on prior SC IFN beta exhibited 
greater improvements in treatment satisfaction with peginter-
feron beta-1a. The reduction in injection frequency likely 
led to reduced ISR frequency in those who had experienced 
ISRs on SC IFN. Different routes of administration may also 
have played a part in differences in convenience scores due 
to lack of familiarity with SC injections in those who had 
been treated with IM IFN beta-1a.
Although the TSQM has previously been utilized as a 
patient-centered end point in RMS, this study is the first 
to demonstrate that peginterferon beta-1a improves global 
satisfaction, specifically side effect and convenience scores, 
in patients with RMS previously treated with nonpegylated 
IFN therapies. Previous studies have utilized the TSQM to 
demonstrate improvements in treatment satisfaction over 
time with other DMTs.17,18 One of these studies found a clini-
cally meaningful relationship between each TSQM domain 
and clinical outcomes such as treatment failure, relapse, and 
AEs leading to discontinuation.17 In another study comparing 
treatment satisfaction in patients switching from a nonpe-
gylated IFN to fingolimod with those remaining on IFN, 
significant improvement in all domains of satisfaction was 
identified.18 Two cross-sectional studies demonstrated dif-
ferences in TSQM scores between DMTs and, in agreement 
with this study, found differences primarily in side effect and 
convenience scores.19,20
The implications of improved treatment satisfaction 
are likely to be substantial, potentially leading to increased 
treatment adherence and, therefore, success.13 For example, 
AEs and perceived lack of effectiveness have been shown to 
impact long-term persistence with treatment.21,22 In addition, 
improvements in convenience scores on the TSQM have been 
associated with improved adherence.20 Since longer treatment 
duration has been linked with improved long-term outcomes 
in patients with RMS,23 components of treatment satisfaction 
that have an impact on persistence and adherence are likely 
to lead to improved treatment success.
Limitations
Limitations of this study include the fact that it was not 
powered to evaluate differences in subgroups, though it did 
include this as a secondary end point that provides important 
insights into what is important to patients, and the fact that 
clinically significant improvement has not been well defined, 
though previous studies have shown relationships between 
clinical outcomes and TSQM domains.17
Conclusions
In summary, patients with RMS who switched from non-
pegylated IFN beta therapies to SC peginterferon beta-1a 
reported significant improvements in satisfaction with 
treatment convenience, side effects, and global satisfac-
tion as early as 4 weeks and continued improvements over 
48 weeks. Regardless of FLS or ISR status, treatment with 
peginterferon beta-1a significantly improved patient-reported 
satisfaction with the convenience of treatment. Although 
peginterferon beta-1a improved treatment satisfaction 
regardless of prior IFN, the greatest improvements in global 
satisfaction and convenience were seen in patients switching 
from SC IFN beta-1a or beta-1b. Due to the administration 
schedule, patients who require a switch may show high levels 
of satisfaction and also find SC peginterferon beta-1a much 
more convenient than previous IFNs. Patient perspective on 
treatment satisfaction is very important to follow in clinical 
practice when considering IFN therapy.
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Table S2 Baseline characteristics of patients enrolled in the ALLOW study
Characteristics ITT population 
(N=201)
Age, years
Mean (sD) 49.8 (9.9)
Median (range) 51 (18–65)
Female, n (%) 163 (81.1)
Time since MS symptom onset, years
Mean (sD) 13.4 (8.5)
Median (range) 12 (1–52)
Time since most recent relapse, mean (SD), years 5.4 (4.62)
Number of relapses within the last year
Mean (sD) 0.2 (0.63)
Median (range) 0 (0–4)
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